1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AA460A7EE5DF2A7F002585930024E8A7
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/best-practices-managing-clinical-trials-during-beyond-covid-19-pandemic
18
19
203.237.94.109
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Clinical Operations Clinical Trial Management

Best Practices for Managing Clinical Trials During and Beyond the COVID-19 Pandemic

ID: CM-9


Features:

5 Info Graphics

14 Data Graphics

90 Metrics

26 Narratives


Pages: 30


Published: 2020


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
The COVID-19 pandemic has altered clinical trials timelines and protocols for many pharmaceutical companies, but technological advancements have enabled savvy drug developers to make continued progress by switching many aspects of on-site clinical trials to virtual modes.

Best Practices, LLC conducted this benchmarking research to identify the best-in-class practices for managing clinical trials during the COVID-19 pandemic. This report examines the impact of COVID-19 pandemic on trials timelines, finances, data collection protocols, and staffing levels.

The report also
analyzes new trends in the management of virtual clinical trials, benefits of virtual clinical trials, and key learnings from industry leaders in managing clinical trials during COVID-19 and beyond.

Industries Profiled:
Medical Device; Biotech; Biopharmaceutical; Clinical Research; Pharmaceutical; Health Care; Computer Software; Telecommunications; Laboratories


Companies Profiled:
Alcon; Alnylam Pharmaceuticals; Aptus Clinical; Atara Biotherapeutics; Cipla; CSL Behring; Cytiva; Idorsia; Kyowa Kirin; MedinCell; Merck; Novartis; Ora; Inc.; Sanofi; United BioSource

Study Snapshot

Best Practices, LLC engaged 18 leaders from 15 life science organizations in this research through a benchmarking survey. More than half of the research participants serve at the director or executive level.

Key topics covered in this report include:

  • Impact of COVID-19 Pandemic on Clinical Trials
  • Virtual Clinical Trials
  • Clinical Trial Data Collection
  • Benefits of Virtual Clinical Trials
  • Staffing Changes During the Pandemic
  • Key Learnings on Managing Trials During the Pandemic


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Delay in Clinical Trials: Many companies have delayed clinical trials by 3 to 6 months. About 2 in 10 trials have halted completely.

  • Enrolment: Companies are enrolling patients through registration links sent over email and video calls. Some companies have also built an app to improve patient enrolment.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Overviewp. 3
Universe of Learningp. 4
Key Insights on Managing Clinical Trials During COVID-19 Pandemicp. 5
II.
Impact on Clinical Trialsp. 7
III.
Virtual Clinical Trialsp. 10
IV.
Data Collectionp. 16
V.
Benefits of Virtual Clinical Trialsp. 19
VI.
Staffing during the Pandemicp. 22
VII.
Key Learningsp. 25
VIII.
Participant Demographicsp. 27
IX.
About Best Practices, LLCp. 30

    List of Charts & Exhibits

    I. Impact on Clinical Trials

    • Impact on timeline of clinical trials due to the additional safety protocols and monitoring processes to be followed; anticipated duration of delay in clinical trial activities
    • Financial impact on organizations due to the delay/halt in clinical trials

    II. Virtual Clinical Trials

    • Executive narratives around virtual trials and telemedicine
    • Switch to remote assessment of the patients involved in a clinical trial since COVID-19; Percentages of trials possible under remote assessment of clinical patients with data monitoring and additional safety protocols
    • Process followed to enroll patients virtually
    • Challenges faced by clinical trial teams in enrolling new participants in this current situation
    • Change in existing patient population dropout rate due to COVID-19

    III. Data Collection

    • Changes made in clinical trials protocols to prevent COVID related obstacles in the gathering of clinical data; Gaps in data gathering in virtual trials because of limited / no access to the medical facility / trial site
    • Effectiveness of the steps taken to ensure accuracy and validity of the data collected remotely during COVID-19

    IV. Benefits of Virtual Clinical Trials

    • Addressing pre-existing challenges faced during on-site clinical trials with the switch to virtual trials
    • Benefits, if any, encountered while remotely conducting virtual clinical trials

    V. Staffing during the Pandemic

    • Changed in staffing levels at trial site since COVID -19;
    • Changes implemented in access to ensure safety (of patients and staff) at clinical trial site (In-patient site and Out-patient site)

    VI. Key Learnings

    • Key learnings on managing the ongoing and new clinical trials during this COVID-19 pandemic